Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37


Specificities of broadly neutralizing anti-HIV-1 sera.

Binley J.

Curr Opin HIV AIDS. 2009 Sep;4(5):364-72. doi: 10.1097/COH.0b013e32832e06fe. Review.


Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L.

J Virol. 2009 Sep;83(17):8925-37. doi: 10.1128/JVI.00758-09. Epub 2009 Jun 24.


Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Stamatatos L, Morris L, Burton DR, Mascola JR.

Nat Med. 2009 Aug;15(8):866-70. doi: 10.1038/nm.1949. Review.


A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, Dawson PE, Burton DR, Zwick MB, Wilson IA.

J Virol. 2009 Sep;83(17):8451-62. doi: 10.1128/JVI.00685-09. Epub 2009 Jun 10.


Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface.

Song L, Sun ZY, Coleman KE, Zwick MB, Gach JS, Wang JH, Reinherz EL, Wagner G, Kim M.

Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9057-62. doi: 10.1073/pnas.0901474106. Epub 2009 May 19.


Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.

Perez LG, Costa MR, Todd CA, Haynes BF, Montefiori DC.

J Virol. 2009 Aug;83(15):7397-410. doi: 10.1128/JVI.00656-09. Epub 2009 May 20.


In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD.

J Virol. 2009 Apr;83(8):3617-25. doi: 10.1128/JVI.02631-08. Epub 2009 Feb 4.


Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R.

J Virol. 2009 Jan;83(2):1045-59. doi: 10.1128/JVI.01992-08. Epub 2008 Nov 12.


Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L.

J Virol. 2009 Jan;83(2):757-69. doi: 10.1128/JVI.02036-08. Epub 2008 Nov 5. Erratum in: J Virol. 2009 May;83(9):4713-5.


Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, Hallahan CW, Migueles SA, Wrammert J, Ahmed R, Nason M, Wyatt RT, Mascola JR, Connors M.

J Virol. 2009 Jan;83(1):188-99. doi: 10.1128/JVI.01583-08. Epub 2008 Oct 15.


Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.

J Virol. 2008 Dec;82(23):11651-68. doi: 10.1128/JVI.01762-08. Epub 2008 Sep 24.


Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study.

van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, Gray CM, Abdool Karim Q, Grobler A, Barnabas N, Iriogbe I, Abdool Karim SS; CAPRISA 002 Acute Infection Study Team.

PLoS One. 2008 Apr 16;3(4):e1954. doi: 10.1371/journal.pone.0001954.


A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3739-44. doi: 10.1073/pnas.0800255105. Epub 2008 Mar 5.


HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Sun ZY, Oh KJ, Kim M, Yu J, Brusic V, Song L, Qiao Z, Wang JH, Wagner G, Reinherz EL.

Immunity. 2008 Jan;28(1):52-63. doi: 10.1016/j.immuni.2007.11.018.


4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.

Gray ES, Moore PL, Bibollet-Ruche F, Li H, Decker JM, Meyers T, Shaw GM, Morris L.

J Virol. 2008 Mar;82(5):2367-75. Epub 2007 Dec 19.


Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Phogat S, Wyatt RT, Karlsson Hedestam GB.

J Intern Med. 2007 Jul;262(1):26-43. Review.


Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L; CAPRISA 002 Study Team.

J Virol. 2007 Jun;81(12):6187-96. Epub 2007 Apr 4.


An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB.

J Virol. 2007 Apr;81(8):4033-43. Epub 2007 Feb 7.


Rational modifications of HIV-1 envelope glycoproteins for immunogen design.

Phogat S, Wyatt R.

Curr Pharm Des. 2007;13(2):213-27. Review.


Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.

Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, Autran B, Barin F.

AIDS. 2006 Oct 3;20(15):1923-30.


Supplemental Content

Support Center